Peptidomimetic proteasome inhibitors
US11203613B2 · kind B2 · utility
4Cited by
5References
22Claims
0Family size
Inventors
Key dates
| Filing date | Oct 11, 2018 |
| Grant date | Dec 21, 2021 |
| Priority date | — |
| Expiry date | Oct 11, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I′): where the substituents R, R1, R3 R4, R′, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.